BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
cell-cell adhesion
,
Ischemia
,
Adipose tissue
,
Neocentromeres
,
Doxorubicin
,
rs2300478
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
human papillomavirus 18
Summary
General Info
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Determination of Human Papillomavirus Type 18 Lineage of E6: A Population Study from Iran.
Phytoconstituents of traditional Himalayan Herbs as potential inhibitors of Human Papillomavirus (HP…
HPV16 and HPV18 Genome Structure, Expression, and Post-Transcriptional Regulation.
Rapid and simultaneous visual typing of high-risk HPV-16/18 with use of integrated lateral flow stri…
Infection with Human Papillomavirus 18 Promotes Alkylating Agent-Induced Malignant Transformation in…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolesce…
Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolesce…
A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.
Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females
Extended Follow Up of Young Women in Costa Rica Who Received Vaccine Therapy for Human Papillomaviru…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ